Sentences with phrase «seqc2 epigenomics»

DURECT's epigenomic regulator program includes the lead molecule DUR - 928 in Phase 1 development.

DURECT Corp. is a biopharmaceutical company focused on two areas of active drug development: New therapeutics based on its proprietary drug delivery platforms and new chemical entities derived from its epigenomic regulator program.

Currently, enhancers can be identified through chromatin - based assays, such as ChIP - seq, which predict enhancer elements indirectly based on the enhancer's association with specific epigenomic marks, such as transcription factors or molecular tags on DNA - associated histone proteins.

«This is exactly the technology you could use to look for epigenomic changes in specific cell types,» says Martienssen, who is also on the International Human Epigenome Consortium's steering committee.

This study opens new avenues of research aiming at integrating genomic and epigenomic data together with environmental exposures in order to elucidate the physio - pathological mechanisms underlying asthma and to promote the development of new therapies.

In a new study published in the journal, Epigenomics, the researchers focused on whether a post-weaning diet, or a diet later in life, could control the epigenome and affect metabolism in the body.

A Berlin - based company called Epigenomics, in partnership with Roche Pharmaceuticals, expects to bring an epigenetic screening test for colon cancer to market by 2008.

In 2008 the National Institutes of Health launched the $ 190 - million Roadmap Epigenomics Project with the goal of cataloguing the epigenetic marks in the major human cell types and tissues.

«However, there is emerging evidence that epigenomic changes such as DNA methylation and histone modifications, which affect the ways in which genes are transcribed and translated into proteins, are important features of these processes,» he continues.

The crew of researchers involved in the Roadmap Epigenomics Project premiered their findings in more than 20 scientific papers published in February (SN: 3/21/15, p. 6).

Dr. Meissner received the GeneExpression Systems Epigenomics Young Innovator Award in 2009, and has frequently published his work in top international journals.

He is now an associate professor at Weill and director of its WorldQuant Initiative for Quantitative Prediction, as well as leader of the U.S. Food and Drug Administration's SEQC2 Epigenomics Quality Control Working Group.

Epigenomics offers insights into the complex, multilayered system of genome regulation.

This exciting new work has been published in the journal Epigenomics.

This may provide clues to treating the disease by using drugs that influence epigenomic function.»

Dr Simone Ottonello, from the University of Parma, Italy says: «If extended to black truffles from different geographic areas, epigenomic analyses, such as the one described in this work, may shed light on the relationships between DNA methylation and transposon - mediated genome shaping, intraspecific variability and commercially relevant organoleptic traits such as aroma and color»

Currently, his group offers standard genomic services to investigators worldwide, including transcriptomics, whole exome sequencing, and epigenomics.

But Epigenomics plans to set up a proprietary database on differences between healthy and diseased tissues to flag, for example, patterns associated with tumors.

Variations in methylation between healthy and ailing tissues «might give us a better understanding of what goes wrong» in some diseases, says Alexander Olek of Epigenomics, a biotech start - up in Berlin.

The researchers used tools of epigenomic analysis to trace the specific epigenetic switches controlling each of thousands of genes in both mouse and human retinal cells as the cells progressed through development.

Residing in large numbers outside the nucleus of every cell, mitochondria contain their own DNA, with unique features that «may require a reassessment of some of our core assumptions about human genetics and evolutionary theory,» concludes Wallace, director of the Center for Mitochondrial and Epigenomic Medicine at The Children's Hospital of Philadelphia.

Epigenomic profiling of complex tissues obscures regulatory elements that distinguish one cell type from another, researchers report.

The overall goal of the TGen study was to look at genomic and epigenomic events to understand the causes of breast cancer brain metastatic lesions, and identify potential new therapeutic targets.

The study, Integrated Genomic and Epigenomic Analysis of Breast Cancer Brain Metastasis, published Jan. 29, is the first of its kind to incorporate all of those avenues of inquiry in the study of this disease.

The maps and discoveries made after examining them are being published February 18 in more than 20 scientific papers in Nature and affiliated journals by a large consortium of researchers involved with the Roadmap Epigenomics Project.

To truly understand the complexities of their biology requires a combination of genomic, epigenomic, and functional analysis.

The paper, «Postnatal diet remodels hepatic DNA methylation in metabolic pathways established by a maternal high - fat diet,» is published in Epigenomics.

Techniques have been developed over the last decade to allow for «epigenomics,» the genome - wide characterization of methylation patterns.

A microfluidic technology was developed and used to probe epigenomic differences between prefrontal cortex and cerebellum.

Epigenomics is presently being used to identify inherited pre-disposition to obesity, diabetes, cardiovascular disease, addiction and psychiatric disorders, as well as markers for aging and cancer progression.

The result is an epigenomic road map that links diseases and traits (red dots) with the locations in the body (white dots) of the switches most correlated with those features; thicker lines correspond to more robust links.

In 2012, for example, Willerslev's lab published an analysis of proteins, which are generally longer lived postmortem than genetic material, of 43,000 - year - old woolly mammoth bones.16 And last year, Willerslev, Orlando, and colleagues published a genome - wide nucleosome map and survey of cytosine methylation levels in the DNA they pulled from the 4,000 - year - old hair shafts of a Paleo - Eskimo, effectively launching the field of ancient epigenetics.17 Also last year, Pääbo's group at the Max Planck Institute for Evolutionary Anthropology published the first full DNA methylation maps of the Neanderthal and Denisovan genomes.18 «For the first time we'll be able to address what is the role of epigenomics and epigenetics in evolution,» Willerslev says.

The Epigenomics Roadmap, the ENCODE Project, and other functional genomics initiatives are just so vital as we expand our search for phenotypically - relevant variants outside of the coding regions.

Next, the authors turned to their other epigenomic profiling datasets — DNA accessibility (DNAse - Seq), methlation (bisulfite sequencing), and RNA transcription (RNA - Seq) to examine and compare the properties of these chromatin states.

Moreover, the regional susceptibility and tolerance to a particular mutation type is a mixture of various genomic and epigenomic features and selective pressures [64].

Highlighted Shared Resource: Epigenomics Profiling Core Facility, managed by Drs. Marcos Estecio and Abhinav Jain provides investigators with cost effective, customized analyses to profile DNA and chromatin modifications.

The NIH Roadmap Epigenomics Consortium has just published the largest collection of epigenomes characterized to date: 111 primary human tissues and cells profiled for histone modification patterns, DNA accessibility, DNA methylation, and gene expression.

One of my favorite papers from this year was the landmark publication of the NIH Epigenomics Roadmap Consortium, which profiled 111 primary human tissues and cell types for histone modification patterns, DNA accessibility, DNA methylation, and gene expression.

John Greally, faculty scholar for epigenomics At Albert Einstein College of Medicine tweeted:

Reference Marks et al., The Transcriptional and Epigenomic Foundations of Ground State Pluripotency, Cell (2012), doi: 10.1016 / j.cell.2012.03.026 Read a review of this paper: Guenther MG and Young RA (2012).

Masafumi now leads his own group at the University of Tsukuba in Japan, with a focus on genomics and epigenomics of clinical samples.

But there is a developing school of research, the study of epigenomics, that seeks to help explain how the interaction of our genes and environment causes disease.

He is the author of over 160 research papers, inventor of 24 patents and patent applications, founder of 4 biotech companies (Genom Analytik GmbH, Biopsytec GmbH and Epigenomics AG, Integragen SA).

Epigenomics.

Genetic data combined with information on gene expression and epigenomics in relevant tissues, and clinical information, can provide clues about the effects of genetic changes within an individual's genome that increase or decrease one's risk of developing type 2 diabetes and its complications, including heart and kidney disease.

Recent advances in single - cell omics and other techniques are revealing variation at genomic, epigenomic, transcriptomic, and posttranscriptomic levels.

The Translational Genomics and Epigenomics Laboratory is part of the Olivia Newton - John Cancer Research Institute.

Epigenomics studies the chemical tags that lie just outside our genes and direct whether particular genes switch on or off.

Researchers are building a database of DNA sequence, functional and epigenomic information, and clinical data from studies on type 2 diabetes and its macro - and microvascular complications, and creating analytic tools to analyze these data.

Omics techniques employed in our group range from whole genome sequencing and epigenomic techniques, to single cell / single strand DNA sequencing (Strand - seq; see Figure 1), the latter of which enables haplotype - resolved studies of genetic variation and genome instability.